Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2022 | Biomarkers associated with PARPi response in patients with castration-resistant prostate cancer

Joe O’Sullivan, MD, Queen’s University, Belfast, UK, explores biomarkers in association with benefit to PARP inhibitors (PARPi) in patients with castration-resistant prostate cancer, including BRCA mutation status. Dr O’Sullivan talks on the importance of developing novel PARP inhibitors that show increased efficacy and reduced toxicity. This interview took place at the European Association of Urology (EAU) Meeting 2022.


Prof. O’Sullivan reports the following conflicts of interest:
Personal fees for Advisory Board and Speaker’s bureau from: AAA/Novartis, Astellas, Bayer, Janssen, Sanofi